The company plans a phased launch for all G7 iOS users everywhere by the end of the second quarter of this year. This means G7 soon becomes the only CGM system that can connect directly to Apple Watch without needing to carry an iPhone. Those who use G7 can access this feature as soon as it launches in their country.
On top of the watch feature, Dexcom announced positive data backing its CGMs and their connectivity to automated insulin delivery (AID). Additionally, the company launched Dexcom ONE+ in new geographies and has more data backing its technology.
The company plans to present much of this evidence and data at ATTD this week in Florence, Italy.
Get the full story at our sister site, Drug Delivery Business News.
Dexcom also announced FDA clearance of its over-the-counter Stelo glucose biosensor.